The idea had personal roots: his grandmother, who suffered from rheumatism and experienced side effects from taking oxycodone, was able to sleep with significantly less pain through the oral intake of cannabis. In a pioneering effort in 2016—long before the legalization of medical cannabis—he decided to dedicate himself to the fight against the stigma surrounding the medication. With a 25 percent market share, Cannamedical leads the German cannabis industry. The company aims to help people with chronic illnesses, especially pain patients, through the import and processing of high-quality medical cannabis products. The focus is on medical care and improving quality of life through many years of experience with medical cannabis. In addition, the company supports the further education of doctors, healthcare professionals, and pharmacists to deepen the understanding of medical cannabis.